The application has been submitted to the regulatory authorities for review. No Duty to Update The information contained in this chart was current as of November 1, 2024. While this pipeline chart remains on the company’s website the company assumes no duty to update the information to reflect...
Food and Drug Administration (FDA) has granted priority review for Merck’s supplemental Biologics License Application (sBLA) based on this study and has set a Prescription Drug User Fee Act (PDUFA), or t...
In addition to providing financial and infrastructure assistance, Merck will offer to coach the start-ups also supported by mentors and enable them to participate in several Page 3 of 4 News Release trainings. At the end of the three months, the companies will be part of Merck's start-up ...
Products 118 In India, we offer a program for our oncology drug Erbitux® that provides financial assistance to eligible underprivileged patients in line with local laws and regulations. Since we initiated the program in 2013, it has been made available to over 7,000 patients nationally. In ...
Merck Access Program Information about insurance coverage and financial assistance options for eligible patients. Clinical trials Learn about our clinical trials and find available studies. Merck Manuals Medical information source covering thousa...
The Merck Access Program provides reimbursement support for patients receiving KEYTRUDA, including information to help with out-of-pocket costs and co-pay assistance for eligible patients. More information is available by calling 855-257...
The Merck Access Program provides reimbursement support for patients receiving KEYTRUDA, including information to help with out-of-pocket costs and co-pay assistance for eligible patients. More information is available by calling 855-257-39...
The Merck Access Program provides reimbursement support for patients receiving KEYTRUDA, including information to help with out-of-pocket costs and co-pay assistance for eligible patients. More information is available b...
President, Merck Research Laboratories. “We look forward to working with the team at Seattle Genetics to advance the clinical program for ladiratuzumab vedotin, which has shown compelling signals of efficacy in early studies, and to bring TUKYSA to even more patients with cancer around the worl...
The Merck Access Program provides reimbursement support for patients receiving KEYTRUDA, including information to help with out-of-pocket costs and co-pay assistance for eligible patients. More information is available by calling 855-257-3932 or visiting www.merckaccessprogram-keytruda.com. About ...